A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

• Status: Completed
• Trial end date: 2015-05-01

Summary

Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis [MS].

Secondary objectives were:

• To assess the effect of the two doses in comparison to interferon beta-1a on:

• Frequency of relapses,

• Fatigue,

• Participant's satisfaction with treatment.

• To evaluate the safety and tolerability of the two doses in comparison to interferon beta-1a.

The study consisted of a core treatment period with a common end date defined as 48 weeks after randomization of the last participant, followed by an optional long-term extension treatment period until teriflunomide is commercially available in accordance with local regulations.

• Phase: Phase 3

Details

• Lead Sponsor: Sanofi
• Treatments: Interferon beta-1a; Interferon-beta; Interferons; Teriflunomide